Vivione Biosciences Announces Agreement With Litmus, LLC For Molecular Design Rights

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Vivione Biosciences Inc. (“Vivione”) (TSXV:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, announced today that through a new agreement (the “Amending Agreement”) with Litmus, LLC (“Litmus”), Vivione has acquired Litmus’ 50 percent royalty interest in net proceeds derived from the Molecular Design technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news